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Abstract
Suicide gene modified donor T cells can improve immune reconstitution after allogeneic haematopoietic stem cell
transplantation (SCT), but can be eliminated in the event of graft versus host disease (GVHD) through the administration of
prodrug. Here we report the production and first-in-man use of mismatched donor T cells modified with a gamma-retroviral
vector expressing a herpes simplex thymidine kinase (HSVTK):truncated CD34 (tCD34) suicide gene/magnetic selection
marker protein. A stable packaging cell line was established to produce clinical grade vector pseudotyped with the Gibbon
Ape Leukaemia Virus (GALV). T cells were transduced in a closed bag system following activation with anti-CD3/CD28 beads,
and enriched on the basis of CD34 expression. Engineered cells were administered in two escalating doses to three children
receiving T-depleted, CD34 stem cell selected, mismatched allogeneic grafts. All patients had pre-existing viral infections
and received chemotherapy conditioning without serotherapy. In all three subjects cell therapy was tolerated without acute
toxicity or the development of acute GVHD. Circulating gene modified T cells were detectable by flow cytometry and by
molecular tracking in all three subjects. There was resolution of virus infections, concordant with detectable antigen-specific
T cell responses and gene modified cells persisted for over 12 months. These findings highlight the suitability of tCD34 as a
GMP compliant selection marker and demonstrate the feasibility, safety and immunological potential of HSVTK-tCD34
suicide gene modified donor T cells.
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Introduction
Allogeneic haematopoietic stem cell transplants (SCT) from
mismatched unrelated donors or haploidentical family donors are
high risk procedures, requiring rigorous T cell depletion to
mitigate against graft versus host disease (GVHD) [1]. Strategies to
remove donor T cells include in-vivo antibody based depletion
through the inclusion of serotherapy (for example Alemtuzumab,
Antithymocyte Globulin, or OKT3) in the conditioning regimen
or by ex-vivo depletion of T cells by magnetic bead based graft
manipulation (for example, through enrichment of stem cells
expressing CD34, or by depletion of T cells expressing CD3 or
abT cell receptors). Whilst stringently T-depleted grafts are less
likely to cause GVHD, they also have reduced anti-viral properties
and often lose graft versus leukaemia effects [2]. One approach
designed to allow the infusion of mismatched donor T cells
involves the stable introduction of a suicide gene to allow
elimination of cells in the event of GVHD though the activation
of specific prodrugs. The most extensively studied system uses gene
modification with Herpes simplex thymdine kinase (HSVTK)
which can activate Ganciclovir to induce cell death, and has now
been tested in a number of clinical trials [3–10]. More recently a
fusion gene encoding an inducible human caspase-9 apoptosis
gene and modified human FK-binding protein has also been
evaluated in pilot studies [11]. One prerequisite for this form of
gene therapy, is the need to ensure that a very high proportion of
infused cells encode the suicide gene, and thus all clinical trials to
date have included linked selection marker genes. Bonini et al
employed Neomycin based selection, subsequently switching to
magnetic bead-antibody based selection of co-expressed truncated
low affinity nerve growth factor receptor (DLNGFR) [3].
Alternatives include a truncated CD19 (DCD19) selection marker,
used to enrich T cells expressing human caspase-9/FK-binding
protein based suicide gene system [11]. Here we describe the first
clinical data using a HSVTK suicide gene fused to a truncated
splice variant of human CD34 (tCD34) [12]. Selection based on
CD34 expression has an important advantage as it can be
combined with Miltenyi CliniMacs reagents which are already
widely used for CD34 stem cell selection. We, and others, have
previously described pre-clinical variants of this system delivered
by gamma-retroviral and HIV lentiviral vectors to human T cells
[12–15]. Here we describe gamma-retroviral gene modification,
enrichment and clinical use of human T cells expressing a
modified HSVTK-CD34 sort-suicide fusion gene in three subjects
following T cell depleted allogeneic SCT. This small study
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provides important proof-of-concept and safety data for the
system.
Materials, Methods and Subject Details
All subjects received treatment at Great Ormond Street
Hospital, London under ethics approval from the UK Gene
therapy advisory committee (GTAC) a national body overseeing
ethical conduct of gene therapy studies. The study was regulated
and monitored by the MHRA, UK. Parents provided written
informed consent on behalf of all children. The protocol (see
Protocol S1) for this study and supporting CONSORT checklist
(see Checklist S1) are available as supporting information.
1. Plasmids and cell lines
A gamma retroviral vector plasmid, encoding long terminal
repeats from Myeloproliferative sarcoma virus (MPSV) and the
leader 71 sequence from MESV and coding for a suicide/sort
fusion gene comprising splice site corrected HSVTK fused to a
truncated splice variant of human CD34 (Figure 1a) has been
previously described [12] and was produced by Geneart
(Germany) along with two independent accessory plasmids
encoding ecotropic env and gag/pol, plasmids. Transiently
produced ecotropic retroviral supernatant was produced in 293T
cells (from a qualified master cell bank) and filtered (0.45 um)
before transduction of PG13 cells (ATCC, CRL-10686), a stable
packaging line producing Gibbon Ape Leukaemia Virus (GALV)
pseudotyped retroviral vector [16]. A high titre clone was selected
under GMP conditions by limiting dilution. Following production
and characterisation of a master cell bank (Table 1), vector was
produced in 10 layer HYPERFlasks (Corning, UK). Vector was
harvested in X-Vivo 10, filtered (0.45 um) and cryopreserved in
100 ml bagged aliquots at 280C. Vector titres were estimated by
flow cytometry for CD34 expression in HT1080 cells. End of
production cells (EOP) and 5% of the vector harvest were
subjected to release test analyses in accordance with harmonised
European pharmacopeia guidelines by Bioreliance (Glasgow,
Scotland) or at the Institute of Child Health, London (Table 1).
2. T cell transduction & selection
Allogeneic donors had completed prior virological screening for
peripheral blood SCT. Donor lymphocytes were subsequently
obtained from ficolled whole blood (P1) or non-mobilised
leukapheresis collection (P2, 3). Cells were re-suspended in gas
Figure 1. Vector configuration and study schema. 1a. A gamma
retroviral platform incorporating long terminal repeals (LTRs) from
Myeloproliferative sarcoma virus (MPSV) and leader sequence 71
derived from Murine embryonic stem cell virus (MESV). The splice site
corrected herpes simplex virus thymidine kinase suicide gene (scHSVTK)
fused to a truncated (splice variant) human CD34 gene is shown. 1b.
Subjects undergoing CD34 selected mismatched allografts and
receiving grafts carrying ,56104 T cells/kg following conditioning
(but not serotherapy) were eligible. Gene modified T cells were
scheduled at two cell doses, the first 56104/kg the day following the
stem cell graft, and the second programmed within 28 days at a higher
dose of 56105/kg. In the event of GVHD.Grade I, Ganciclovir therapy
was scheduled for seven days to eliminate gene modified T cells.
doi:10.1371/journal.pone.0077106.g001
Table 1. Release characterisation of retroviral stocks.
Investigation Test Article Method Specification
*Replication competent retroviruses
(RCR)
EOP cells PG4 S+L- Assay No CPE detected
**Titre of the produced supernatant Vector supernatant Flow analysis .105 infectious particles/ml detected on
basis of CD34 expression
**Transgene functionality Vector supernatant MTT assay Survival of T cells transduced with HSVTK
,20% at concentrations of GCV at 10 mM,
and absence of viable cells detected on
trypan blue staining
*Sterility of the cells Vector supernatant BacTec No microbial growth detected
**Replication competent retroviruses
(RCR)
Vector supernatant PG4 S+L- Assay No CPE detected
*Endotoxin Vector supernatant Chromogenic kinetic LAL test ,5 EU/ml.
*Mycoplasma by indicator cell culture Vector supernatant Culture and Immunofluorescence No mycoplasma detected
*Adventitious pathogens Vector superntatant Inoculation of adult and suckling mice, and
guinea pigs
No viral contamination detected
*Undertaken by Bioreliance (Glasgow, Scotland) under harmonised European pharmacopeia.
**Institute of Child Health, London. A similar schedule of characterisation was applied to the PG13 Master cell bank.
doi:10.1371/journal.pone.0077106.t001
HSVTK-CD34 T Cells
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permeable 100 ml cell differentiation bags (Miltenyi biotech,
Germany) at 106/ml in X-Vivo 10 (Lonza, Belgium) supplemented
with 5% human AB serum (Lonza, USA) and 100 u/ml of human
recombinant interleukin 2 (Proleukin, Novartis, USA,) and
activated with DynabeadsH ClinExVivoTM CD3/CD28 (Invitro-
gen, UK) at a ratio of 1:1. Cell density was maintained in the
range of 0.5–1.06106/ml throughout with additional IL2 supple-
mentation very 48 hrs. Two rounds of vector exposure were
undertaken after 48 and 72 hours with CH-296 coated bags
(RetroNectin, Takara bio Inc, Japan), preloaded with retrovirus by
centrifugation. Following semi-automated magnetic bead removal
using a Dynal ClinExVivo MPC (Invitrogen, UK) cells were rested
overnight before using CliniMacs CD34 selection kit (Miltenyi
biotech, Germany) to select CD34 expressing transduced T cells.
Transduction efficiency and purification were assessed using
mouse anti-human CD34 PE conjugated mAb (BD Biosciences,
Europe) stained and analysed using flow cytometry (BD Biosci-
ences), Cells were again rested overnight and then cryopreserved
in dose aliquots of 56104/kg and 56105/kg. Reagents are detailed
in Table 2 and the transduction procedures provided in full in
Table 3.
3. Assessment of sensitivity to the prodrug Ganciclovir
Transduced T cells were exposed to 10 uM Ganciclovir (GCV,
Roche Limited, UK) and after 72 hours viability was assessed in
triplicate by spectrophotometry using a 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide assay (MTT, Sigma, USA) as
previously described [17]. The assay measures mitochondrial
activity and thus background levels of up to 20% were detectable
even when no cells were sufficiently viable to mediate trypan blue
exclusion.
Table 2. GMP T cell transduction reagents.
Reagents Cat no/Lot no Company
X VIVO 10 8SP200 Lonza, Belgium
L-glutamine 17-905C Lonza, USA
Human AB serum 14-498E Lonza, USA
Recombinant Human Interleukin-2 (IL-2) [Proleukin] 00101/0936 Novartis, USA; Procured via Great Ormond Street Pharmacy
CD3 and CD28 Beads [DynabeadsH ClinExVivoTM CD3/CD28] 402.03D Invitrogen, Norway
GMP-grade CH-296 (RetroNectin) T100B Takara Bio Inc, Japan
CliniMacs CD34 selection kit 171-01 Miltentyi Biotech, Germany
CliniMACS TUBING SET 161-01 Miltentyi Biotech, Germany
100 ml cell differentiation Bags 170-076-400 Miltentyi Biotech, Germany
Phosphate Buffer Saline/EDTA 700-25 Miltentyi Biotech, Germany
doi:10.1371/journal.pone.0077106.t002
Table 3. GMP compliant T cell transduction procedure.
Day 1 Activation 1.Resuspend cells at 16106/ml in multiple 100 ml Miltenyi bags; 2.Coat 26 number of T cell bags with
retronectin (1 mg/ml in 10 ml PBS)
Day 3 Transduction Round 1 1.Thaw vector; 2.Remove RN from bags and add 50 ml vector per bag; 3.Spin bags at 1000 g, 40 min; 4.Transfer
cell suspension to each bag (1:1 ratio)
Day 4 Transduction Round 2 1.Thaw vector; 2. Remove RN from bags and add vector; 3. Spin bags at 1000 g, 40 min; 4. Volume reduce; 5.
Add IL2 to final concentration 100 u/ml
Day 6 Culture Add IL2 to final concentration 100 u/ml
Day 7 Bead removal 1.Assess CD34 expression by flow cytometry; 2 Remove CD3/CD28 beads using MagSep (Dynal); 3.Rest overnight
in X-Vivo 10+5% AB serum+IL2 100 u/ml
Day 8 Positive selection 1.CliniMacs selection of CD34+ T cells; 2.Rest overnight in X-Vivo 10+5% AB serum+IL2 100 u/ml
Day 9 Dose preparation 1.Flow cytometry for CD34 purity; 2.Phenotype analysis by flow cytomtetry; 3.Archive samples for RCR testing;
4.Cryopreserve cells in dose aliquots
doi:10.1371/journal.pone.0077106.t003
Table 4. Production of donor HSVTK-CD34 T cells.
Patients P1 P2 P3
Donor type MMUD Haplo Haplo
CD3 after transduction 99% 97% 88%
CD3+CD4+ 78% 28% 49%
CD3+CD8+ 21% 65% 50%
Transduction efficiency 5.1% 5.2% 6.3%
Purification 92% 96% 93%
Viability 96% 92% 93%
Transduced T cell number 316106 576106 1906106
% survival in 10 uM GCV 20% 13% 11%
Dose1 (,56104/kg) 1.86106 2.56105 3.46105
Dose2 (,56105/kg) 17.56106 5.06106 Not given
doi:10.1371/journal.pone.0077106.t004
HSVTK-CD34 T Cells
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4. Proliferation and alloreactivity responses
To assess alloreactivity T cells and irradiated (30 Gy) stimulator
cells were suspended at 106/ml in X-vivo 10/5% AB serum and
stimulator cells and 100 ul of each plated in relevant autologou-
s:allogeneic combinations, in triplicate in 96-U well plates. After a
5 day culture, cells were pulsed with 0.5 mCi/well 3H-thymidine
Figure 2. Transduction, enrichment and suicide gene function. (a) Flow cytometry of peripheral blood lymphocytes after transduction. Cells
were activated with anti-CD3/28 beads and underwent two rounds of exposure to vector before removal of activation beads and magnetic bead
enrichment using a CliniMacs device. (b) Transduced T cells were enriched (CD34+) to .90% purity for all three products. (c) Upon exposure to the
prodrug Ganciclovir (GCV, 10 uM), engineered cells from all three donors had reduced survival compared to non-modified controls (P,0.001). Means
of triplicate wells and standard error of means are shown.
doi:10.1371/journal.pone.0077106.g002
HSVTK-CD34 T Cells
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(Amersham Bioscience) for 16 hours and were then harvested onto
a filtermat using a Wallac 96 well plate harvester. Radioactive
incorporation was measured using a Wallac counter. Responses to
polyclonal stimulation by anti-human CD3 (OKT3, Ebioscience,
UK) were also assessed in the presence or absence of 10 uM GCV.
5. Transfer and tracking of T cell mediated virus specific
immunity
Virus specific responses were assessed in subjects and donors
(where possible) using an IFN-c secretion assay-detection kit (PE)
(Miltenyi Biotech, Germany). Following overnight stimulation with
relevant antigens adenovirus hexon (ADV, Miltenyi Biotec,
Germany), Varicella zoster (VZV) and H1N1 (National Institute
for Biological Standards and Control (NIBSC), UK) or staphylo-
coccal enterotoxin B (SEB, Sigma, UK), IFN-c secreting cells were
labelled using a bi-specific monoclonal antibody, specific for both
IFN-c and CD45. Cells were stained in RPMI/1% AB serum and
cultured at 37uC for 45 minutes. The IFN-c positive secreting cells
were labelled using IFN-c PE detection Ab, anti-CD8FITC mAb
(Becton Dickinson,USA), and APC-labelled CD4 mAb (Becton
Dickinson, USA), and then analyzed by flow cytometry.
6. Regulatory Approvals, patient characteristics and
procedures
All subjects were treated under approvals secured from the UK
Medicine and Healthcare Products Regulatory Agency (MHRA)
and Gene therapy advisory committee (GTAC). P2 and P3 were
treated as part of a registered clinical trial (NCT01204502) and P1
treated following approval from both MHRA and GTAC.
All three subjects received grafts comprising CD34 selected
peripheral blood stem cells (PBSC) following chemotherapy
conditioning without serotherapy, and received an initial dose of
56104/kg HSVTK-CD34 modified T cells, within one day of
stem cell grafting. All received prophylaxis against GVHD with
Cyclosporin in combination with Mycophenolate Mofetil (MMF).
P1, a child with Fanconi anaemia, was the recipient of a second
mismatched unrelated donor (MMUD) graft following relapse of
MDS following an initial reduced intensity procedure. P2 and P3
were infants undergoing paternal haploidentical (haplo) PBSCT to
treat severe combined immunodeficiencies (SCID) and had pre-
existing viral complications with H1N1 influenza (P2) and
Adenovirus (P3).
Figure 3. T cell repertoire diversity before and after modification. Complementarity determining region-3 (CDR3) T-cell receptor (TCR)
spectratyping was performed as previously described [18]. Briefly, RNA was extracted and cDNA prepared from pre- and post-transduced cells.
Twenty four Vb-specific primers were used with a fluorescent-labelled constant region (Cb)-specific primer to RT-PCR amplify the CDR3 region of the
TCR b chain. Products were run on an AB3130 Genetic Analyzer and analysed using GeneMapper v4.0 software (Applied Biosystems, Warrington, UK).
Representative data for P2 is showing preservation Vb family distributions is shown.
doi:10.1371/journal.pone.0077106.g003
HSVTK-CD34 T Cells
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Statistical analysis
Where indicated, student t tests were applied to cell prolifer-
ation and survival data.
Results and Discussion
Production of HSVTK-CD34 gene modified T cells
A replication defective gamma retroviral vector suitable for T
cell modification, with intact long terminal repeat promoter
elements, and encoding a splice site corrected HSVTK-tCD34
fusion gene was produced under GMP conditions using a stable
producer clone expressing accessory packaging genes and the
Gibbon Ape Leukaemia Virus envelope (see M&M). Previous
clinical trials have used vectors encoding HSVTK linked to
neomycin resistance and/or DLNGFR [3,4,8]. We used an
abbreviated transduction and selection process lasting 8 days,
employing anti-CD3/CD28 activation beads and animal serum-
free conditions, which preserved T cell repertoire diversity and
retained T cell alloreactivity and antiviral function as previously
described [18]. The entire process, including CliniMacs based
CD34 selection of engineered T cells was performed using closed
bag systems under GMP compliant conditions. Details of
transduction efficiency, magnetic bead mediated enrichment and
cell yields are provided in Table 4. In all three cases, between 5–
6% of donor T cells were modified (Figure 2a) ensuring low vector
copy numbers and these cells were then enriched on the basis of
CD34 expression to 92–96% purity to produce target cell doses for
infusion (Figure 2b). Flow cytometry confirmed that the majority
of cells (88–99%) were CD3+ T cells, with the expected sensitivity
to GCV in vitro (Figure 2c). T cell receptor repertoires were
Gaussian with all families represented (Figure 3). Modified T cells
exhibited GCV sensitive anti-CD3 mediated proliferation and
alloreactivity against allogeneic irradiated peripheral blood
mononuclear cells (Figure 4).
First-in-man use of HSVTK-CD34 T cells
All subjects underwent CD34 selected mismatched stem cell
grafting after conditioning which did not include any form of
serotherapy. Infusions of HSVTKCD34 T cells (56104/kg) were
tolerated in all subjects without any acute toxicities (Figure 5).
Only P1 developed skin GVHD (Grade I) and this was self-
limiting, not requiring additional systemic therapy. Of note, the
study protocol, under the direction of UK regulatory authorities,
limited the maximum dose of donor T cells to 56105/kg, a dose
not expected to cause significant GVHD and lower than that used
in previous trials where GVHD was encountered more frequently.
Unfortunately, P1 was transplanted in the presence of relapsed
MDS, and remission was not achieved after escalated dose cell
therapy (56105/kg). However, reactivation of localized varicella
zoster infection was rapidly controlled and T cell responses against
VZV antigen were detectable in peripheral blood using an
interferon gamma capture assay (not shown). P2 (RAG1 deficient
SCID) was transplanted with pre-existing H1N1 influenza
colonisation which was resistant to Oseltamavir and was requiring
ongoing Zanamavir therapy. The halpoidentical donor was
vaccinated against influenza, including the 2009 pandemic
H1N1 strain and specific interferon-c based responses were
detectable in the enriched gene modified T cell donation (Figure 6).
The subject received both programmed cell doses without
developing GVHD and over the following months eradicated
H1N1 influenza. Specific responses were detectable in peripheral
blood for over 12 months (Figure 6), although cellular immune
reconstitution was slow and disrupted by autoimmune haemolysis
requiring systemic therapy with corticosteroids and Rituximab.
Nonetheless, by twelve months after transplantation, there was
robust T cell recovery mediated by de novo thymopoieisis.
Persistence of HSVTKCD34 T cells was documented throughout
this period and interestingly recent post pandemic studies of T cell
responses against H1N1 have reported similar interferon mediated
T cell responses in transplant and vaccinated hosts [19]. P3
suffered from a radiation sensitivity disorder (Ligase IV deficiency)
with pre-existing infectious complications including pneumocystis
carinii, rhinovirus, enterovirus and adenovirus. The patient
developed significant early mucositis following conditioning. There
was a notable but transient rise in peripheral blood T cells within
two weeks of SCT but no evidence of GVHD. Virus specific
responses against adenovirus hexon antigen were detectable in the
donor and the child after cell infusion (not shown). However, the
Figure 4. Proliferation and alloreactivity responses. In the upper
panel, CD34TK modified T cells were co-cultured with irradiated
allogeneic peripheral blood monuclear stimulator cells and proliferation
was measured by 3H-thymidine incorporation. Cells mounted significant
responses against allogeneic target cells (p = 0.02) whereas in the
presence of 10 uM GCV, proliferation was significantly reduced
(p = 0.05). In the lower panel, proliferation of gene modified T cell
responses following polyclonal stimulation by anti-human CD3 were
abrogated in the presence of 10 uM GCV (P,0.01). Means of triplicate
wells with standard error of mean are shown.
doi:10.1371/journal.pone.0077106.g004
HSVTK-CD34 T Cells
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Figure 5. T cell reconstitution in patients after cell therapy. P1, a child with Fanconi anaemia, underwent a second mismatched donor, CD34
selected stem cell graft after in the context of relapsed MDS. Donor HSVTK/CD34 modified T cells were infused in two dose aliquots and were
detectable at low level in peripheral blood for over 12 weeks before the patient died of disease relapse. The persistence of non-modified T cells
reflects the reduced intensity conditioning and absence of serotherapy. P2, an infant with RAG1 deficient SCID had no pre-existing T cell immunity
and was conditioned whist infected with H1N1 influenza. Modified T cells persisted for over 12 months, with eventual recovery of thymic derived
donor T cells after one year and normalisation of immunity. P3 suffered Ligase IV deficiency, a form of radiosensitive SCID. Expansion of modified
donor T cells was detected within two weeks of first infusion, but the patient died from mucositis related pulmonary and gastrointestinal
haemorrhage before dose escalation.
doi:10.1371/journal.pone.0077106.g005
HSVTK-CD34 T Cells
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Figure 6. Transfer and tracking of T cell mediated virus specific immunity. Most compelling, and beneficial, was transfer of immunity
against pandemic H1N1 infulenza in P2. The haploidentical donor had been electively vaccinated against the strain before leukapheresis harvest of
peripheral blood lymphocytes. The transduced and CD34 enriched populations exhibited specific IFNc responses against HI1N1 compared to non-
stimulated control cells. Samples collected 150 days after donor lymphocyte infusion from the patient showed similar H1N1 specific IFNc responses,
which coincided with clearance of persistent H1N1 respiratory infection. These responses were still detectable after 350 days.
doi:10.1371/journal.pone.0077106.g006
HSVTK-CD34 T Cells
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underlying radiosenstivity disorder probably predisposed to severe
the mucositis following conditioning, and subsequent catastrophic
gastrointestinal and pulmonary haemorrhage occurred before the
second dose of cell therapy, and in absence of apparent GVHD.
We were able to demonstrate T cell mediated, antigen specific
responses against reactivating viruses, Varicella zoster (P1), H1N1
(P2) and Adenovirus (P3). These viruses are often problematic after
SCT and whilst they can often be partially controlled with
antiviral drugs, require intact cellular immunity for clearance [20].
The beneficial antiviral effects may have been mediated by both
engineered and non-modified T cell populations, but unfortu-
nately because of the low frequency of detectable virus specific
populations and low lymphocyte counts in peripheral blood
following SCT, it was not possible to characterise effector cells in
detail. However, clearance of similar viral pathogens after T cell
depleted transplants generally requires several months of immune
recovery. We found that there was delay of almost 12 months in
P2 until significant thymic mediated T cell reconstitution
occurred, and in the interim he presumably benefited from
adoptive transfer of anti-H1N1 immunity from the donor.
Furthermore, it has been reported adult patients receiving TK
modified T cells experience greater than expected levels of
thymopoiesis and it has been postulated that this may be mediated
by increased levels of IL-7 following donor lymphocyte infusion
[21]
Whilst the HSVTK element in our vector is potentially
immunogenic, responses were not anticipated in the immuodefi-
cient subjects treated here. Previous trials using suicide gene
modified T cells documented clearance of engineered T cells in
immunocompetent subjects who mounted immune responses
against HSVTK or NeoR antigens [22]. Alternative non-
immunogenic humanised suicide genes are being developed, most
notably inducible variants of caspase genes, which have recently
been used in pilot studies, although access to the dimerising agent
required to elicit cell death is restricted [11].
In summary we have demonstrated under GMP conditions the
feasibility of T cell modification and selection using a HSVTK-
tCD34 suicide/selection system, and provide first-in-man data for
this approach in the setting of mismatched allogeneic SCT. Whilst
GVHD was not problematic at the cell doses administered,
recovery of specific antiviral immunity was demonstrated in all
three subjects. The reagents and procedures are readily adaptable
for other gene based therapies, including emerging anti-tumour
and anti-viral cellular therapies.
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